ASH 2023 | Hot topics in the AML space: menin inhibitors
Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, comments on the most exciting areas of research in the treatment of patients with acute myeloid leukemia (AML), with a primary focus on menin inhibitors. This class of targeted agents have shown encouraging results in several mutational subtypes of AML and Dr Fathi expresses his excitement regarding future research into these agents, both as monotherapy and in combination. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy and advisory activities: Amgen, Servier, Takeda, Orum, Daiichi Sankyo, Menarini, Rigel, Remix, Abbvie, Astellas, BMS, Ipsen, Gilead, Pfizer, Genentech, AstraZeneca, Autolus, Syndax
Clinical trial funding: Abbvie, Servier, BMS
